P1.01-13 Efficacy and Safety of Concurrent Anti-Tuberculosis Treatment and Chemotherapy in Lung Cancer Patients with Co-Existent Tuberculosis

Abstract

This study evaluated the safety and efficacy of concurrent anti-tuberculosis (TB) and chemotherapy in patients with advanced lung cancer and active tuberculosis in a large sample size. We retrospectively analyzed treatment naïve patients with advanced lung cancer diagnosed at Guangzhou Chest Hospital from 2015 to 2017. These patients were categorized into two groups: lung cancer patients without a history of TB treated with first-line standard anti-cancer chemotherapy (group A) and lung cancer patients with active TB treated concurrently with anti-TB and first-line chemotherapy (group B). Patients in group A were matched (2:1) to patients in group B with similar age, stage and tumor histology. Adverse events (AEs) and objective response rate (ORR) were tested using Chi-square test or Fisher’s exact tests. Time to treatment failure (TTF) and overall survival (OS) were evaluated with Kaplan-Meier method and compared with the log-rank test. A total of 99 patients were eligible (group A, n=66; group B, n=33). Grade ≥3 treatment-related AEs (TRAEs), primarily hematologic toxicity, occurred in 41% and 48% of patients, for the A versus B groups, respectively. The hepatic insufficiency in two groups was generally grades 1 or 2, and their incidences were similar (26% and 27%, respectively). After two cycles of chemotherapy, ORR was 42.4% in group A and 33.3% in group B, which did not show any significant difference (P = .383). There were also not statistically significant in TTF (median, 7.0 vs 5.6 months for groups A and B, p= .175) and OS (median, 17.0 vs 14.0 months, p= .312). Among group B patients, rates of sputum negative conversion and lesion absorption were 100% within 3 months, and no recurrence was observed within 1 year. Compared with chemotherapy alone in lung cancer patients, the combination of anti-TB treatment and chemotherapy did not increase hematological toxicity and hypohepatia of chemotherapy in lung cancer patients with pulmonary TB, which was safety and feasibility.